Selank vs DSIP: Anxiolytic Peptide vs Endogenous Sleep Regulator

Selank and DSIP are both research-stage neuropeptides with CNS activity, but they differ substantially in origin, mechanism, evidence depth, and regulatory standing. Selank is a synthetic heptapeptide derived from the natural immunomodulatory peptide tuftsin, developed in Russia and approved there in 2009 as an intranasal anxiolytic with a well-characterized GABAergic and neurotrophic mechanism. DSIP (delta sleep-inducing peptide) is an endogenous nonapeptide first isolated in 1974 and studied across sleep architecture modulation, neuroendocrine signaling, antioxidant defense, and neuroprotection, with an evidence base that remains preclinical and lacks a confirmed receptor target.

Key Differentiators at a Glance

Mechanism Side by Side

Selank: GABAergic Modulation and Neurotrophic Factor Enhancement

Selank is a heptapeptide built on the tuftsin sequence (Thr-Lys-Pro-Arg) with a Pro-Gly-Pro stabilizing group appended to improve metabolic stability and CNS penetration. Its principal mechanism involves allosteric modulation of GABA-A receptors. Unlike benzodiazepines, which bind directly to the benzodiazepine site and force GABA-A into a high-conductance state, Selank modulates GABA-A through a distinct allosteric interaction that enhances inhibitory neurotransmission without producing sedation or dependency. The resulting increase in GABAergic tone in the amygdala and limbic circuits suppresses anxiety-related signaling while preserving cortical arousal needed for cognitive function.

Alongside GABAergic activity, Selank upregulates BDNF and NGF expression in the hippocampus and prefrontal cortex, supporting neuroplasticity. Serotonin metabolism is normalized through effects on tryptophan hydroxylase and monoamine oxidase activity, contributing to mood stabilization and anxiety reduction beyond the acute GABA effect. Because Selank also retains the immunomodulatory properties of its parent peptide tuftsin, it modulates IL-6 and T-cell balance, making it one of the few anxiolytic compounds with a documented dual CNS-immune profile. Intranasal administration provides direct CNS access via the olfactory pathway, bypassing first-pass hepatic metabolism.

flowchart TD
    Selank["Selank\n(Thr-Lys-Pro-Arg-Pro-Gly-Pro)"]
    Selank --> GABA["GABA-A Receptor\n(allosteric modulation)"]
    Selank --> NTF["BDNF / NGF\nupregulation"]
    Selank --> SERO["Serotonin metabolism\nnormalization (5-HT axis)"]
    Selank --> IMM["Immunomodulation\n(IL-6, T-cell balance via tuftsin)"]
    GABA --> ANX["Anxiolysis\n(amygdala/limbic suppression)"]
    GABA --> COG["Preserved cognition\n(no sedation)"]
    NTF --> NP["Neuroplasticity\nHippocampus / PFC"]
    SERO --> MOOD["Mood stabilization"]
    IMM --> IMMUNE["Immune balance\n(stress-related immune support)"]

DSIP: Neuroendocrine Axis Modulation Without a Confirmed Receptor

DSIP (Trp-Ala-Gly-Gly-Asp-Ala-Ser-Gly-Glu) is an endogenous peptide first isolated by Monnier and colleagues from rabbit cerebral venous blood in 1974 (PMID: 4606802). Unlike Selank, DSIP has no cloned, confirmed receptor. Its pharmacological profile is inferred from functional outcomes across multiple neuroendocrine systems. Research has documented effects on the GHRH/somatostatin axis, which stimulates GH release, the CRH axis, which attenuates stress-induced ACTH elevation in rodents, and LH pulsatility. In the CNS, DSIP promotes slow-wave sleep in rabbits and rodents, though human sleep studies have produced inconsistent replication. Endogenous DSIP plasma concentrations follow a circadian pattern, peaking at night in humans.

A mechanistically distinct line of DSIP research concerns antioxidant enzyme induction. In aging rats, DSIP upregulated superoxide dismutase (SOD), catalase, and glutathione peroxidase gene expression in brain and blood (PMID: 25257425). Preclinical stroke models showed reduced infarct volume following systemic DSIP administration (PMID: 34500605), and the structurally related KND analog (Lys-Asn-Asp) reduced brain and myocardial infarction in rodents during reperfusion (PMID: 33918965). The phosphorylated form, pDSIP, penetrates the blood-brain barrier more effectively via the phosphorylated Ser7 residue and restored spatial memory alongside CREB phosphorylation in rats exposed to high-altitude hypoxia (PMID: 30107169). The absence of a defined receptor leaves DSIP’s mechanism genuinely incomplete and limits hypothesis-driven drug development.

Evidence Strength

Selank: Clinical Approval Anchored in Russian Regulatory Record

Selank’s evidence base is the stronger of the two. The compound was approved in Russia in 2009 following clinical trials in generalized anxiety disorder. Over 15 years of clinical use has generated observational safety and efficacy data from human populations. Published preclinical and clinical work characterizes the GABA modulation and BDNF upregulation mechanisms, and controlled human studies demonstrated anxiolytic efficacy comparable to low-dose benzodiazepines without sedation, cognitive impairment, or withdrawal symptoms. Gene expression analyses have identified modulation of over 50 genes related to anxiety, immunity, and neuroplasticity in hippocampal tissue, providing a broad mechanistic substrate for the observed effects.

The majority of published clinical work originates from Russian institutions. Selank lacks FDA or EMA approval, and independent replication under Western regulatory standards is limited. The clinical data should be read with that framing in mind, but its volume and the 15-year clinical use record still distinguish Selank substantially from compounds with purely preclinical evidence.

DSIP: Preclinical Breadth Without Robust Clinical Replication

DSIP’s evidence base spans five decades and multiple research programs, but it remains preclinical in its most important claims. The 1984 Schneider-Helmert and Schoenenberger double-blind crossover trial in chronic insomnia is the most cited human study; it showed improved sleep efficiency and reduced nocturnal waking in a small cohort, but independent replication has not been robust. No Phase 2 or Phase 3 clinical trial for DSIP appears on ClinicalTrials.gov as of April 2026. The neuroprotection findings (PMID: 34500605, PMID: 33918965) are rodent data. The antioxidant enzyme induction data (PMID: 25257425) comes from aging rat studies.

The pDSIP high-altitude study (PMID: 30107169) is among the more mechanistically informative pieces of evidence, showing CREB phosphorylation as a downstream correlate of improved sleep and memory. This suggests a molecular convergence with Selank’s BDNF/neuroplasticity axis, but the finding remains a single preclinical study and does not establish clinical utility. Russian and Eastern European observational reports exist for DSIP-derived preparations (deltalycyn), but their study designs limit interpretation.

Safety Profile Differences

Selank’s tolerability profile is relatively well-characterized through clinical use. Reported adverse effects are mild and transient: nasal mucosal irritation in approximately 10-15% of intranasal users, mild drowsiness at higher doses in around 5-10% of users, a brief unpleasant taste as the solution reaches the pharynx (common but benign), and some initial enhancement of emotional awareness consistent with anxiety reduction and neural recalibration. No physical dependency, tolerance development, withdrawal syndrome, or significant adverse events have been documented across 15 years of clinical use. The absence of a benzodiazepine-site interaction is mechanistically consistent with this profile.

DSIP’s safety profile is far less defined. Early human studies reported no serious adverse effects, but the total human exposure in controlled studies is small. DSIP is an endogenous peptide, which is often cited as a tolerability indicator, but endogenous origin does not guarantee safety of exogenous administration at pharmacological concentrations. No systematic human toxicology dataset for DSIP exists. Hepatoprotective properties have been observed in restraint stress models (PMID: 26902351), which is mechanistically interesting but does not constitute a human safety profile. The circadian plasma variation and apparent normal physiology of endogenous DSIP provide baseline biological context, not pharmacological safety data.

Practical Research Context Differences

Selank is administered intranasally, with the olfactory pathway providing direct CNS access. The pharmacokinetics are reasonably characterized: anxiolytic effects begin within 15-30 minutes of intranasal administration and persist 4-8 hours, with cumulative benefits on baseline anxiety developing over 1-2 weeks. The compound is stable under standard peptide storage conditions and has been formulated as a standardized nasal spray in the Russian clinical product. Its research application space is defined by its clinical history: anxiety disorders, stress resilience, cognitive performance under stress, and immunomodulation are studied domains with both mechanistic rationale and human data.

DSIP presents different research challenges. No standardized administration route has been validated for human research. Animal studies have used intracerebroventricular, intravenous, and intraperitoneal routes; each implies different CNS access profiles and pharmacokinetic interpretations. Peripheral bioavailability of native DSIP is complicated by rapid hydrolysis. Phosphorylation at Ser7 improves CNS penetration and duration in animal models but adds synthetic complexity. Researchers working with DSIP must navigate the lack of a defined receptor, the orphan pharmacology problem, and the absence of validated human protocols for any endpoint. The compound’s research space (sleep, neuroendocrinology, antioxidant biology, neuroprotection) is broader but less actionable than Selank’s.

Selank has also been studied in combination with Semax in Russian clinical protocols, providing a starting framework for researchers interested in anxiolytic-nootropic combinations. DSIP has no documented combination research with other neuropeptides in controlled settings.

When Researchers Choose Selank

Selank is the appropriate compound when the research question concerns anxiolytic pharmacology, GABA-A receptor modulation outside the benzodiazepine site, or non-sedating anxiety intervention in preclinical or translational models. Its defined receptor pharmacology provides a tractable molecular target for mechanistic studies. Researchers studying the intersection of anxiety and cognitive performance benefit from Selank’s well-documented property of reducing anxiety while preserving or enhancing cognitive output. This dual profile is rare in the anxiolytic literature.

Selank is also relevant to researchers working on immunomodulation in the context of stress-related immune suppression. The tuftsin-derived immunomodulatory properties, confirmed in studies showing cytokine modulation and T-cell balance effects, position Selank as a tool for studying CNS-immune interactions. Its intranasal delivery route and 15-year clinical record in Russia provide a human safety context that research-only peptides cannot offer.

When Researchers Choose DSIP

DSIP is the appropriate compound when the research question specifically concerns sleep architecture modulation, endogenous sleep-regulatory peptide biology, or neuroendocrine axis interactions at the hypothalamic-pituitary level. Its status as an endogenous peptide with circadian plasma variation makes it directly relevant to chronobiology research. The compound’s multi-axis neuroendocrine effects, spanning GHRH, CRH, and LH interactions, position it for research into hypothalamic-pituitary signaling as an integrated system rather than a single receptor target.

DSIP is also relevant for researchers examining the blood-brain barrier delivery problem. Its documented BBB penetration, enhanced by Ser7 phosphorylation, has made the peptide a scaffold for CNS drug delivery research (PMID: 28462721, PMID: 25063142). The 2024 study examining a Pichia pastoris-secreted DSIP fusion construct in an insomnia model (PMID: 39444618) illustrates how DSIP’s BBB transport properties are being leveraged in contemporary delivery research. Groups developing peptide-based CNS delivery systems may find DSIP’s known transport biology more directly relevant than compounds with less characterized CNS access routes.

The neuroprotection findings in stroke and reperfusion models, while preliminary, support a role for DSIP-derived sequences in cytoprotective research. The KND analog data (PMID: 33918965) in particular suggests that DSIP-derived peptides may represent a tractable scaffold for developing cardio- and neuroprotective compounds, even if the parent peptide’s clinical path remains undefined.

Closing

Selank and DSIP represent two distinct research trajectories within neuropeptide science. Selank arrives with defined receptor pharmacology, a characterized anxiolytic and neurotrophic mechanism, and a clinical history that places it in a category above most research peptides despite its absence from Western regulatory approval. DSIP arrives as an endogenous molecule with a broad but mechanistically incomplete research record, whose fundamental pharmacology, specifically a receptor target, remains unresolved after more than fifty years of study. Neither compound should be interpreted outside the research context. Selank, despite Russian clinical approval, lacks regulatory authorization in most Western markets. DSIP has no established clinical application anywhere. Both compounds merit continued investigation, but they address different scientific questions and carry different evidentiary weights.

For detailed background on each compound, see the research hubs:

• Selank Research Hub
• DSIP Research Hub

See also

Individual research hubs:

• Selank research
• Dsip research

Peptide family:

• Nootropic Peptides

Shared pathway context:

• Neuropeptides & Cognitive Function

Related comparisons:

• Dsip vs GHK-Cu
• Semax vs Dsip